期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 59, 期 3, 页码 788-809出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.5b00828
关键词
-
资金
- BrightFocus Foundation
- Pew Scholars Program in Biomedical Sciences
- National Eye Institute [R01EY021205]
- Georgia Tech Molecular Biophysics Senior Award
- Glaucoma Research Foundation
Glaucoma, a heterogeneous ocular disorder affecting similar to 60 million people worldwide, is characterized by painless neurodegeneration of retinal ganglion cells (RGCs), resulting in irreversible vision loss. Available therapies, which decrease the common causal risk factor of elevated intraocular pressure, delay, but cannot prevent, RGC death and blindness. Notably, it is changes in the anterior segment of the eye, particularly in the drainage of aqueous humor fluid, which are believed to bring about changes in pressure. Thus, it is primarily this region whose properties are manipulated in current and emerging therapies for glaucoma. Here, we focus on the challenges associated with developing treatments, review the available experimental methods to evaluate the therapeutic potential of new drugs, describe the development and evaluation of emerging Rho-kinase inhibitors and adenosine receptor ligands that offer the potential to improve aqueous humor outflow and protect RGCs simultaneously, and present new targets and approaches on the horizon.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据